查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859714

外泌體診斷和治療市場預測至2032年：按產品/服務、來源、類型、技術、最終用戶和地區分類的全球分析

Exosome Diagnostics and Therapeutics Market Forecasts to 2032 - Global Analysis By Product & Service (Instruments, Reagents & Kits, Software, Services and Consumables), Source, Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球外泌體診斷和治療市場規模將達到 1.0808 億美元，到 2032 年將達到 74.861 億美元，預測期內複合年成長率將達到 83.2%。

外泌體診斷和治療涉及對細胞釋放的攜帶蛋白質、脂質和核酸的小型細胞外囊泡的研究和應用，旨在將其作為疾病檢測和治療的工具。在診斷方面，外泌體可作為非侵入性生物標記物，透過液態切片即時監測癌症、神經退化性疾病和心血管疾病等病理狀況。在治療方面，可以透過基因工程改造外泌體，使其能夠將藥物、RNA和基因編輯分子直接遞送至目標細胞，從而提高治療精準度並減少副作用。該領域充分利用了外泌體的天然生物相容性、穩定性和細胞特異性靶向潛力，使其成為個人化醫療和下一代臨床干預的理想平台。

增加研究經費和政府支持

公共和私人基金會正在投資基於外泌體的液體液態切片，用於癌症篩檢和再生醫學。該平台支援腫瘤學、神經病學和感染疾病的生物標記發現、藥物遞送和免疫調節。與學術研究型醫院網路和培養箱的整合增強了檢驗和擴充性。轉化醫學和個人化醫療計畫正在推動對非侵入性、精準工具的需求。這些因素正在推動該平台在以研究為密集、創新主導的醫療保健生態系統中廣泛應用。

缺乏標準化通訊協定

不同實驗室供應商和治療藥物開發商的分離鑑定和定量方法差異很大。純度標記、載重分析和功能檢測方面缺乏共識，使得驗證和監管申報變得複雜。企業在比較不同研究的數據以及在GMP條件下擴大生產規模方面面臨挑戰。監管機構要求採用統一的標準來評估診斷和治療應用中的安全性、有效性和品質。這些限制阻礙了平台成熟度和跨領域整合。

慢性病和感染疾病的流行情況

外泌體在癌症、心血管疾病和神經退化性疾病的早期檢測、疾病監測和標靶遞送方面具有獨特的優勢。相關平台支援透過液態切片進行免疫分析，並利用基於RNA的有效載荷進行治療調控。與主導的分析和多組體學工作流程的整合，可提高靈敏度、特異性和臨床效用。在人口老化和疾病負擔沉重的地區，對可擴展、微創解決方案的需求日益成長。這些趨勢正在推動以疾病為中心的外泌體創新和應用的發展。

高昂的成本和基礎設施需求

分離純化需要微流體技術和奈米顆粒追蹤系統，這導致巨大的資本和營運成本。在GMP條件下進行生產和臨床級驗證進一步增加了成本和複雜性。小規模實驗室和新興生物技術公司在獲得可擴展生產的資金和基礎設施方面面臨挑戰。缺乏保險報銷和有限的臨床指南進一步限制了該技術在診斷和治療領域的應用。這些限制持續限制該平台在資源匱乏且分散的醫療環境中的部署。

新冠疫情的影響：

疫情擾亂了整個外泌體平台的臨床試驗供應鏈和研究項目。封鎖和資源重新分配延緩了樣本採集、檢測方法開發和法規核准。然而，隨著研究人員對免疫反應、病毒持續存在和長期後遺症的研究，人們對基於外泌體的診斷方法的興趣激增。對遠端液態切片採樣和數位病理學的投資加速了平台創新和部署。消費者和臨床領域對分子診斷和個人化醫療的認知度不斷提高。這些變化強化了對外泌體基礎設施和轉化研究的長期投資。

預計在預測期內，診斷業務板塊將成為最大的業務板塊。

由於臨床相關檢測技術的成熟以及其在疾病領域的廣泛應用，預計在預測期內，診斷領域將佔據最大的市場佔有率。基於外泌體的診斷技術利用RNA、蛋白質和脂質生物標記物，支持早期檢測、預後和治療監測。該平台採用液態切片和免疫測量，從血液、尿液和唾液中分離和分析外泌體。結合人工智慧主導的解讀和多組體學分析，可提高檢測的敏感度、特異性和長期追蹤能力。腫瘤學、感染疾病、神經退化等領域對非侵入性且可擴展的診斷技術的需求日益成長。

預計在預測期內，幹細胞領域將以最高的複合年成長率成長。

預計在預測期內，幹細胞領域將呈現最高的成長速度，因為外泌體療法正拓展至再生醫學和免疫調節領域。幹細胞來源的外泌體在整形外科、心血管和神經系統疾病中發揮組織修復、發炎控制和神經保護的作用。間質幹細胞和誘導性多功能幹細胞是實現規模化生產、載體工程和靶向遞送的理想平台。與生物材料和3D支架的整合能夠提高治療效果和標靶性。在高齡化社會和慢性病族群中，對無細胞、免疫安全性高的治療方法的需求日益成長。這些趨勢正在推動幹細胞來源的外泌體療法和遞送平台的發展。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的研究基礎設施、積極的監管參與以及外泌體平台在臨床上的廣泛應用。企業和學術機構正在腫瘤學、神經病學和感染疾病計畫中部署診斷和治療方法，並整合定序和生物資訊工作流程。對液態切片活體組織切片轉化研究和個人化醫療的投資支持了擴充性和檢驗。領先的診斷研究中心和監管機構的存在推動了創新和標準化。各公司正根據FDA指南、NIH資助和支付方參與情況調整其平台策略。這些因素共同推動了北美在外泌體商業化和臨床整合的領先地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這得益於醫療現代化降低了疾病負擔，以及生物技術投資在區域經濟中的匯聚。中國、印度、日本和韓國等國家正在公共衛生、學術研究和新興企業診斷領域推廣外泌體平台。政府支持的舉措正在推動基礎設施建設、新創公司孵化以及生物標記發現和治療方法檢驗的國際合作。本地企業正在提供經濟高效且符合當地實際情況的解決方案，以滿足疾病特徵和合規性需求。腫瘤學、感染疾病、再生醫學等領域對可擴展且符合當地文化的外泌體平台的需求正在成長。

免費客製化服務：

訂閱本報告的用戶可享有以下免費客製化服務之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 研究方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究方法
  • 研究材料
    • 原始研究資料
    • 二手研究資料
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球外泌體診斷和治療市場（按產品和服務分類）

  • 裝置
  • 試劑和試劑盒
  • 軟體
  • 服務
  • 消耗品

6. 全球外泌體診斷與治療市場（依來源分類）

  • 血
  • 電漿
  • 尿
  • 幹細胞
  • 其他來源

7. 全球外泌體診斷與治療市場（按類型分類）

  • 診斷
  • 治療藥物
  • 研究用途

8. 全球外泌體診斷與治療市場（依技術分類）

  • 外泌體分離技術
    • 超速離心
    • 尺寸排阻層析法
    • 親和性和捕獲
    • 微流體
  • 表徵工具
    • NTA（奈米顆粒追蹤分析）
    • 穿透式電子顯微鏡（TEM）
    • 掃描電子顯微鏡（SEM）
    • 西方印漬術
    • 流式細胞技術
  • 其他技術

9. 全球外泌體診斷與治療市場（依最終使用者分類）

  • 醫院和診所
  • 診斷檢查室
  • 癌症研究所
  • 學術和研究機構
  • 生物製藥公司
  • 其他最終用戶

第10章 全球外泌體診斷與治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Catalent Inc.
  • Fujifilm Diosynth Biotechnologies Inc.
  • WuXi Advanced Therapies Inc.
  • Samsung Biologics Co., Ltd.
  • AGC Biologics Inc.
  • Minaris Regenerative Medicine GmbH
  • Oxford Biomedica plc
  • Charles River Laboratories International Inc.
  • Recipharm AB
  • Merck KGaA
  • Takara Bio Inc.
  • Miltenyi Biotec BV & Co. KG
  • BioNTech SE
Product Code: SMRC31938

According to Stratistics MRC, the Global Exosome Diagnostics and Therapeutics Market is accounted for $108.08 million in 2025 and is expected to reach $7486.1 million by 2032 growing at a CAGR of 83.2% during the forecast period. Exosome diagnostics and therapeutics involve the study and application of exosomes tiny extracellular vesicles released by cells that carry proteins, lipids, and nucleic acids-as tools for disease detection and treatment. In diagnostics, exosomes serve as non-invasive biomarkers, providing real-time insights into conditions like cancer, neurodegenerative disorders, and cardiovascular diseases through liquid biopsies. Therapeutically, engineered exosomes can deliver drugs, RNA, or gene-editing molecules directly to target cells, enhancing precision and reducing side effects. The field leverages exosomes' natural biocompatibility, stability, and cell-specific targeting potential, making them a promising platform for personalized medicine and next-generation clinical interventions.

Market Dynamics:

Driver:

Increased research funding and government support

Public agencies and private foundations are investing in exosome-based liquid biopsy cancer screening and regenerative medicine. Platforms support biomarker discovery drug delivery and immune modulation across oncology neurology and infectious diseases. Integration with academic research hospital networks and biotech incubators enhances validation and scalability. Demand for non-invasive and precision-focused tools is rising across translational and personalized medicine programs. These dynamics are propelling platform deployment across research-intensive and innovation-driven healthcare ecosystems.

Restraint:

Lack of standardized protocols

Isolation characterization and quantification methods vary widely across labs vendors and therapeutic developers. Absence of consensus on purity markers cargo profiling and functional assays complicates validation and regulatory submission. Enterprises face challenges in comparing data across studies and scaling manufacturing under GMP conditions. Regulatory bodies require harmonized standards to assess safety efficacy and quality across diagnostic and therapeutic applications. These constraints continue to hinder platform maturity and cross-sector integration.

Opportunity:

Growing prevalence of chronic and infectious diseases

Exosomes offer unique advantages in early detection disease monitoring and targeted delivery across cancer cardiovascular and neurodegenerative conditions. Platforms support liquid biopsy immune profiling and RNA-based payloads for therapeutic modulation. Integration with AI-driven analytics and multi-omics workflows enhances sensitivity specificity and clinical utility. Demand for scalable and minimally invasive solutions is rising across aging populations and high-burden disease areas. These trends are fostering growth across disease-centric exosome innovation and deployment.

Threat:

High costs and infrastructure requirements

Isolation and purification require ultracentrifugation microfluidics and nanoparticle tracking systems with high capital and operational expenditure. Manufacturing under GMP conditions and clinical-grade validation adds to cost and complexity. Smaller labs and emerging biotech firms face challenges in securing funding and infrastructure for scalable production. Lack of reimbursement and limited clinical guidelines further constrain adoption across diagnostic and therapeutic settings. These limitations continue to restrict platform deployment across resource-constrained and decentralized healthcare environments.

Covid-19 Impact:

The pandemic disrupted clinical trials supply chains and research programs across exosome platforms. Lockdowns and resource reallocation delayed sample collection assay development and regulatory review. However interest in exosome-based diagnostics surged as researchers explored immune response viral persistence and long-term sequelae. Investment in liquid biopsy remote sampling and digital pathology accelerated platform innovation and deployment. Public awareness of molecular diagnostics and personalized medicine increased across consumer and clinical segments. These shifts are reinforcing long-term investment in exosome infrastructure and translational research.

The diagnostics segment is expected to be the largest during the forecast period

The diagnostics segment is expected to account for the largest market share during the forecast period due to its clinical relevance assay maturity and broad applicability across disease areas. Exosome-based diagnostics support early detection prognosis and treatment monitoring using RNA proteins and lipid biomarkers. Platforms use liquid biopsy microfluidics and immunoassays to isolate and analyze exosomes from blood urine and saliva. Integration with AI-driven interpretation and multi-omics profiling enhances sensitivity specificity and longitudinal tracking. Demand for non-invasive and scalable diagnostics is rising across oncology infectious diseases and neurodegeneration.

The stem cells segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the stem cells segment is predicted to witness the highest growth rate as exosome therapeutics expand across regenerative medicine and immune modulation. Stem cell-derived exosomes support tissue repair inflammation control and neuroprotection across orthopedic cardiovascular and neurological indications. Platforms enable scalable production cargo engineering and targeted delivery using mesenchymal and induced pluripotent stem cells. Integration with biomaterials and 3D scaffolds enhances therapeutic efficacy and localization. Demand for cell-free and immunologically safe therapies is rising across aging populations and chronic disease cohorts. These dynamics are accelerating growth across stem cell-derived exosome therapeutics and delivery platforms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure regulatory engagement and clinical adoption across exosome platforms. Enterprises and academic institutions deploy diagnostics and therapeutics across oncology neurology and infectious disease programs with integrated sequencing and bioinformatics workflows. Investment in liquid biopsy translational research and personalized medicine supports scalability and validation. Presence of leading diagnostic firms research centers and regulatory bodies drives innovation and standardization. Firms align platform strategies with FDA guidance NIH funding and payer engagement. These factors are propelling North America's leadership in exosome commercialization and clinical integration.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization disease burden and biotech investment converge across regional economies. Countries like China India Japan and South Korea scale exosome platforms across public health academic research and clinical diagnostics. Government-backed initiatives support infrastructure development startup incubation and international collaboration across biomarker discovery and therapeutic validation. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. Demand for scalable and culturally aligned exosome platforms is rising across oncology infectious diseases and regenerative medicine.

Key players in the market

Some of the key players in Exosome Diagnostics and Therapeutics Market include Thermo Fisher Scientific Inc., Bio-Techne Corporation, QIAGEN N.V., System Biosciences LLC, ReNeuron Group plc, Hitachi Chemical Diagnostics Inc., Capricor Therapeutics Inc., Evox Therapeutics Limited, Capital Biosciences Inc., Exogenus Therapeutics S.A., Exo Biologics S.A., AMSBIO LLC, Lonza Group AG, NanoView Biosciences Inc. and Aethlon Medical Inc.

Key Developments:

In August 2025, Bio-Techne announced the divestiture of Exosome Diagnostics Inc. to Mdxhealth SA, including the ExoDx Prostate (EPI) test, its CLIA-certified clinical laboratory, and related assets. The deal enables Mdxhealth to expand its urology diagnostics portfolio, while Bio-Techne retains access to proprietary exosome-based technology for future kit development under its precision diagnostics growth pillar.

In April 2025, Thermo Fisher introduced ExoTrack(TM) Ultra, a next-gen exosome isolation and profiling kit designed for liquid biopsy applications. The product supports high-yield recovery and multiplexed biomarker detection, enabling early-stage cancer diagnostics and neurodegenerative disease monitoring. It integrates seamlessly with Thermo's mass spectrometry and NGS platforms, enhancing translational research and clinical workflows.

Product & Services Covered:

  • Instruments
  • Reagents & Kits
  • Software
  • Services
  • Consumables

Sources Covered:

  • Blood
  • Plasma
  • Urine
  • Stem Cells
  • Other Sources

Types Covered:

  • Diagnostics
  • Therapeutics
  • Research Use

Technologies Covered:

  • Exosome Isolation Techniques
  • Characterization Tools
  • Other Technologies

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Cancer Institutes
  • Academic & Research Institutions
  • Biopharma Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Exosome Diagnostics and Therapeutics Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Reagents & Kits
  • 5.4 Software
  • 5.5 Services
  • 5.6 Consumables

6 Global Exosome Diagnostics and Therapeutics Market, By Source

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Plasma
  • 6.4 Urine
  • 6.5 Stem Cells
  • 6.6 Other Sources

7 Global Exosome Diagnostics and Therapeutics Market, By Type

  • 7.1 Introduction
  • 7.2 Diagnostics
  • 7.3 Therapeutics
  • 7.4 Research Use

8 Global Exosome Diagnostics and Therapeutics Market, By Technology

  • 8.1 Introduction
  • 8.2 Exosome Isolation Techniques
    • 8.2.1 Ultracentrifugation
    • 8.2.2 Size-Exclusion Chromatography
    • 8.2.3 Immunoaffinity Capture
    • 8.2.4 Microfluidics
  • 8.3 Characterization Tools
    • 8.3.1 NTA (Nanoparticle Tracking Analysis)
    • 8.3.2 TEM (Transmission Electron Microscopy)
    • 8.3.3 SEM (Scanning Electron Microscopy)
    • 8.3.4 Western Blotting
    • 8.3.5 Flow Cytometry
  • 8.4 Other Technologies

9 Global Exosome Diagnostics and Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Cancer Institutes
  • 9.5 Academic & Research Institutions
  • 9.6 Biopharma Companies
  • 9.7 Other End Users

10 Global Exosome Diagnostics and Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Lonza Group AG
  • 12.3 Catalent Inc.
  • 12.4 Fujifilm Diosynth Biotechnologies Inc.
  • 12.5 WuXi Advanced Therapies Inc.
  • 12.6 Samsung Biologics Co., Ltd.
  • 12.7 AGC Biologics Inc.
  • 12.8 Minaris Regenerative Medicine GmbH
  • 12.9 Oxford Biomedica plc
  • 12.10 Charles River Laboratories International Inc.
  • 12.11 Recipharm AB
  • 12.12 Merck KGaA
  • 12.13 Takara Bio Inc.
  • 12.14 Miltenyi Biotec B.V. & Co. KG
  • 12.15 BioNTech SE

List of Tables

  • Table 1 Global Exosome Diagnostics and Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Exosome Diagnostics and Therapeutics Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Exosome Diagnostics and Therapeutics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Exosome Diagnostics and Therapeutics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 5 Global Exosome Diagnostics and Therapeutics Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Exosome Diagnostics and Therapeutics Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Exosome Diagnostics and Therapeutics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Exosome Diagnostics and Therapeutics Market Outlook, By Source (2024-2032) ($MN)
  • Table 9 Global Exosome Diagnostics and Therapeutics Market Outlook, By Blood (2024-2032) ($MN)
  • Table 10 Global Exosome Diagnostics and Therapeutics Market Outlook, By Plasma (2024-2032) ($MN)
  • Table 11 Global Exosome Diagnostics and Therapeutics Market Outlook, By Urine (2024-2032) ($MN)
  • Table 12 Global Exosome Diagnostics and Therapeutics Market Outlook, By Stem Cells (2024-2032) ($MN)
  • Table 13 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other Sources (2024-2032) ($MN)
  • Table 14 Global Exosome Diagnostics and Therapeutics Market Outlook, By Type (2024-2032) ($MN)
  • Table 15 Global Exosome Diagnostics and Therapeutics Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 16 Global Exosome Diagnostics and Therapeutics Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 17 Global Exosome Diagnostics and Therapeutics Market Outlook, By Research Use (2024-2032) ($MN)
  • Table 18 Global Exosome Diagnostics and Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 19 Global Exosome Diagnostics and Therapeutics Market Outlook, By Exosome Isolation Techniques (2024-2032) ($MN)
  • Table 20 Global Exosome Diagnostics and Therapeutics Market Outlook, By Ultracentrifugation (2024-2032) ($MN)
  • Table 21 Global Exosome Diagnostics and Therapeutics Market Outlook, By Size-Exclusion Chromatography (2024-2032) ($MN)
  • Table 22 Global Exosome Diagnostics and Therapeutics Market Outlook, By Immunoaffinity Capture (2024-2032) ($MN)
  • Table 23 Global Exosome Diagnostics and Therapeutics Market Outlook, By Microfluidics (2024-2032) ($MN)
  • Table 24 Global Exosome Diagnostics and Therapeutics Market Outlook, By Characterization Tools (2024-2032) ($MN)
  • Table 25 Global Exosome Diagnostics and Therapeutics Market Outlook, By NTA (Nanoparticle Tracking Analysis) (2024-2032) ($MN)
  • Table 26 Global Exosome Diagnostics and Therapeutics Market Outlook, By TEM (Transmission Electron Microscopy) (2024-2032) ($MN)
  • Table 27 Global Exosome Diagnostics and Therapeutics Market Outlook, By SEM (Scanning Electron Microscopy) (2024-2032) ($MN)
  • Table 28 Global Exosome Diagnostics and Therapeutics Market Outlook, By Western Blotting (2024-2032) ($MN)
  • Table 29 Global Exosome Diagnostics and Therapeutics Market Outlook, By Flow Cytometry (2024-2032) ($MN)
  • Table 30 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 31 Global Exosome Diagnostics and Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Exosome Diagnostics and Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 Global Exosome Diagnostics and Therapeutics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Exosome Diagnostics and Therapeutics Market Outlook, By Cancer Institutes (2024-2032) ($MN)
  • Table 35 Global Exosome Diagnostics and Therapeutics Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
  • Table 36 Global Exosome Diagnostics and Therapeutics Market Outlook, By Biopharma Companies (2024-2032) ($MN)
  • Table 37 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.